Shire Announces Launch Of FOSRENOL(R) In Japan - Management Of Hyperphosphataemia In End-Stage Renal Disease Patients (Medical News Today) PDF Print

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announces the Japanese launch of FOSRENOL(R) (lanthanum carbonate), which is now available to prescribers and patients in Japan through Shire's strategic alliance partner Bayer Yakuhin Ltd.

read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.